Filing Analysis
ImmuCell Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. All proposed measures, including the election of directors and the ratification of the auditor, were approved.
📋 Key Facts
- The 2026 Annual Meeting was held via remote communication on June 11, 2026.
- 7,397,695 shares were represented, accounting for over 81% of total outstanding eligible votes.
- Seven director nominees were elected to one-year terms.
- The 2025 Stock Option and Incentive Plan was approved (90.39% of voting shares).
- Wipfli LLP was ratified as the Independent Registered Public Accounting Firm for the year ending December 31, 2026.
- An amendment to the Certificate of Incorporation regarding the exculpation of officers was approved.
ImmuCell Corporation announced a two-phase manufacturing capacity expansion program to pivot resources from its Re-Tain® product to its flagship First Defense® product line. The first phase involves renovating facilities and adding a new freeze dryer to meet growing demand.
📋 Key Facts
- Board of Directors authorized the expansion program on June 4, 2026.
- Phase 1 involves renovating the former Re-Tain® facility and adding a new freeze dryer.
- Phase 1 is estimated to cost approximately $3.5 million and take 12 months to complete.
- Phase 2 will focus on repurposing Re-Tain® equipment and adding automation to expand First Defense® colostrum processing capacity.
- The company previously suspended in-house manufacturing of Re-Tain® in late 2025/early 2026.
ImmuCell Corporation reported its unaudited financial results for the first quarter ended March 31, 2026. The announcement was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- Unaudited financial results for the quarter ended March 31, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Press release dated April 14, 2026 included as Exhibit 99.1, despite the filing date of May 14, 2026
ImmuCell Corporation has entered into a Settlement Deed with Norbrook Laboratories Limited to resolve all claims related to a 2019 Development Services and Commercial Supply Agreement. Under the terms of the settlement, Norbrook will pay ImmuCell $2 million following the expiration of their previous agreement on March 31, 2026.
🚩 Red Flags
- Expiration of the underlying 2019 Development Services and Commercial Supply Agreement as of March 31, 2026, which may impact future revenue streams.
📋 Key Facts
- Settlement Deed signed on May 8, 2026, with Norbrook Laboratories Limited.
- Norbrook to pay ImmuCell a sum of $2,000,000.
- The settlement resolves claims related to a 2019 Development Services and Commercial Supply Agreement.
- The underlying agreement expired on March 31, 2026.
- The deed includes confidentiality undertakings and no admission of liability.
ImmuCell Corporation announced a significant board refresh involving the resignation of three directors and the appointment of two new members with deep industry expertise. The departures include former long-time CEO Michael Brigham and current VP of Sales Bobbi Jo Brockmann, effective April 15, 2026.
🚩 Red Flags
- Simultaneous departure of three board members, representing a significant loss of institutional knowledge.
- Departure of the former long-term CEO from the board less than a year after his retirement as CEO.
📋 Key Facts
- Three directors (Bryan K. Gathagan, Michael F. Brigham, and Bobbi Jo Brockmann) are resigning or retiring from the Board effective April 15, 2026.
- Michael F. Brigham served as President and CEO for over 25 years (2000-2025) and has been a director since 1999.
- Bobbi Jo Brockmann will remain the Company’s Vice President of Sales and Marketing despite resigning from the Board.
- New director Gilles Guillemette, DVM, brings 30+ years of experience from Elanco, Bayer, and Trupanion.
- New director Anthony DiMarco, Ph.D., brings 21 years of experience from IDEXX as VP of R&D and Global Manufacturing.
- A new Strategy & Technology Committee has been formed, which both new directors will join.
ImmuCell Corporation announced preliminary unaudited sales results for the first quarter of 2026, reporting a 28.4% increase in product sales compared to the first quarter of 2025. The disclosure was made via a press release on April 8, 2026, following the close of the quarter on March 31, 2026.
📋 Key Facts
- Preliminary unaudited product sales for Q1 2026 increased by 28.4% compared to Q1 2025.
- The reporting period ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Timothy C. Fiori, Chief Financial Officer.
ImmuCell Corporation announced that director Steven A. Rosgen will retire from the Board effective April 1, 2026, following a previous notice of non-reelection. Kathy V. Turner, a former executive at IDEXX Laboratories and Abbott Laboratories, has been elected to fill the vacancy and will chair the Compensation and Stock Option Committee.
📋 Key Facts
- Steven A. Rosgen tendered his resignation on March 12, 2026, effective April 1, 2026.
- Kathy V. Turner was elected to the Board effective April 1, 2026.
- Ms. Turner will serve on the Audit Committee and as Chair of the Compensation and Stock Option Committee.
- Ms. Turner brings over 30 years of experience, including roles as Chief Marketing Officer at IDEXX Laboratories and leadership positions at Abbott Laboratories.
- The transition was previously signaled in an 8-K filed on February 9, 2026.
ImmuCell Corporation announced its unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on March 4, 2026, reporting on the period ended December 31, 2025.
- The report includes both quarterly and full-year unaudited financial results.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Timothy C. Fiori, CFO, signed the report.